Standard BioTools Inc. (LAB)
NASDAQ: LAB · Real-Time Price · USD
0.6620
-0.0225 (-3.29%)
Aug 18, 2026, 4:00 PM EDT - Market closed
Standard BioTools Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 84.6 | 85.33 | 91.01 | 106.34 | 97.95 | 128.85 |
Other Revenue | - | - | - | - | - | 1.73 |
| 84.6 | 85.33 | 91.01 | 106.34 | 97.95 | 130.58 | |
Revenue Growth | -4.78% | -6.24% | -14.42% | 8.57% | -24.99% | -5.47% |
Cost of Revenue | 41.89 | 42.79 | 46.13 | 55.89 | 60.9 | 99.15 |
Gross Profit | 42.71 | 42.54 | 44.88 | 50.45 | 37.05 | 31.43 |
Selling, General & Admin | 86.93 | 109.86 | 103.06 | 87.54 | 102.29 | 98.89 |
Research & Development | 18.42 | 25.99 | 28.83 | 25.95 | 33.86 | - |
Operating Expenses | 105.35 | 135.85 | 131.89 | 113.49 | 136.14 | 98.89 |
Operating Income | -62.64 | -93.31 | -87.01 | -63.04 | -99.09 | -67.46 |
Interest Expense | -0.03 | -0.03 | -3.32 | -4.57 | -4.33 | -3.82 |
Interest & Investment Income | 11.94 | 9.18 | 20.2 | 5.57 | 2.23 | - |
Other Non Operating Income (Expenses) | -3.42 | 5 | -5.01 | 1.39 | -60.9 | 7.62 |
EBT Excluding Unusual Items | -54.15 | -79.16 | -75.13 | -60.64 | -162.09 | -63.66 |
Merger & Restructuring Charges | -32.83 | -16.94 | -40.48 | -13.56 | -13.59 | - |
Gain (Loss) on Sale of Investments | -0.6 | -0.6 | - | - | - | - |
Asset Writedown | - | - | - | - | -3.53 | - |
Other Unusual Items | -3.4 | - | 25.21 | - | -13.72 | - |
Pretax Income | -90.98 | -96.7 | -90.4 | -74.2 | -192.93 | -63.66 |
Income Tax Expense | -37.05 | -37.88 | 0.54 | 0.45 | -2.83 | -4.42 |
Earnings From Continuing Operations | -53.93 | -58.83 | -90.94 | -74.66 | -190.1 | -59.24 |
Earnings From Discontinued Operations | 138.84 | -16.07 | -47.95 | - | - | - |
Net Income | 84.91 | -74.9 | -138.89 | -74.66 | -190.1 | -59.24 |
Preferred Dividends & Other Adjustments | - | - | 46.01 | - | - | - |
Net Income to Common | 84.91 | -74.9 | -184.9 | -74.66 | -190.1 | -59.24 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 387 | 382 | 353 | 79 | 78 | 76 |
Shares Outstanding (Diluted) | 387 | 382 | 353 | 79 | 78 | 76 |
Shares Change | 2.76% | 8.03% | 346.24% | 1.09% | 3.32% | 5.19% |
EPS (Basic) | 0.22 | -0.20 | -0.52 | -0.94 | -2.43 | -0.78 |
EPS (Diluted) | 0.22 | -0.20 | -0.52 | -0.94 | -2.43 | -0.78 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -82.58 | -82.65 | -151.81 | -46.12 | -93.2 | -57.33 |
Free Cash Flow Per Share | -0.21 | -0.22 | -0.43 | -0.58 | -1.19 | -0.76 |
Gross Margin | 50.48% | 49.86% | 49.32% | 47.44% | 37.83% | 24.07% |
Operating Margin | -74.04% | -109.34% | -95.60% | -59.28% | -101.17% | -51.66% |
Profit Margin | 100.36% | -87.77% | -203.17% | -70.20% | -194.08% | -45.36% |
Free Cash Flow Margin | -97.61% | -96.85% | -166.81% | -43.37% | -95.15% | -43.90% |
EBITDA | -53.07 | -82.33 | -70.15 | -47.86 | -84.06 | -63.81 |
EBITDA Margin | -62.73% | -96.48% | -77.08% | -45.01% | -85.82% | -48.86% |
D&A For EBITDA | 9.56 | 10.98 | 16.86 | 15.18 | 15.03 | 3.65 |
EBIT | -62.64 | -93.31 | -87.01 | -63.04 | -99.09 | -67.46 |
EBIT Margin | -74.04% | -109.34% | -95.60% | -59.28% | -101.17% | -51.66% |
Revenue as Reported | 84.6 | 85.33 | 91.01 | 106.34 | 97.95 | 130.58 |
Advertising Expenses | - | 2.2 | 2.6 | 2 | - | 3.4 |